Nicholas Lorusso, an analyst from TD Cowen, maintained the Buy rating on Kiniksa Pharmaceuticals. The associated price target remains the same with $60.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nicholas Lorusso has given his Buy rating due to a combination of factors that highlight Kiniksa Pharmaceuticals’ strong performance and growth potential. The company’s Q3 sales for Arcalyst reached $181 million, marking a significant 15% increase quarter-over-quarter and a 61% rise year-over-year, surpassing consensus expectations by 8%. This growth is attributed to increased patient enrollments, a larger prescriber base, and extended treatment durations, indicating robust demand and market penetration.
Furthermore, Kiniksa’s management has raised their 2025 sales guidance for Arcalyst by 6%, reflecting confidence in continued sales acceleration. The expansion of the prescriber base and the growing number of repeat prescribers underscore the potential for further market capture. With Arcalyst having penetrated only a fraction of its target market, there remains substantial opportunity for growth, which supports the Buy rating assigned by Nicholas Lorusso.
In another report released on October 20, Citi also maintained a Buy rating on the stock with a $50.00 price target.
Based on the recent corporate insider activity of 125 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KNSA in relation to earlier this year.